| Code | CSB-RA004937MB2HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to Frexalimab, targeting CD40 ligand (CD40LG), also known as CD154. CD40LG is a type II transmembrane protein primarily expressed on activated T cells that plays a critical role in immune regulation by binding to CD40 on antigen-presenting cells. This interaction is essential for T cell-dependent B cell activation, immunoglobulin class switching, and the formation of germinal centers. Dysregulated CD40-CD40LG signaling has been implicated in various autoimmune and inflammatory conditions, including systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, and transplant rejection.
Frexalimab is a next-generation anti-CD40LG antibody engineered with an Fc-silent mutation to minimize thromboembolic complications associated with earlier CD40LG-targeting therapeutics. This biosimilar antibody serves as a valuable research tool for investigating CD40-CD40LG pathway biology, studying immune cell interactions, and exploring therapeutic mechanisms in autoimmune disease models. It enables researchers to evaluate costimulatory blockade strategies and advance understanding of T cell-B cell crosstalk in various immunological contexts.
There are currently no reviews for this product.